Grown Rogue International (GRUSF) Asset Writedowns and Impairment (2015 - 2025)
Grown Rogue International's (GRUSF) quarterly Asset Writedowns and Impairment came in at $26715.0 in Q1 2025, up 1127.15% year-on-year from $2177.0 in Q1 2024, and up 367.15% quarter-over-quarter from -$10000.0 in Q3 2024.
Grown Rogue International (GRUSF) Asset Writedowns and Impairment (2015 - 2025) Analysis & Trends
Grown Rogue International's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $26715.0 for Q1 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 1127.15% year-over-year to $26715.0 in Q1 2025; TTM through Jun 2025 was $16715.0, a 90.93% decrease from a year earlier, with the FY2023 full-year figure at $87699.0, changed N/A from the prior year.
- Asset Writedowns and Impairment advanced to $26715.0 in Q1 2025 per GRUSF's latest filing, from -$10000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $168144.0 in Q1 2023 and bottomed at -$10000.0 in Q3 2024.
- The 4-year median for Asset Writedowns and Impairment is $13881.0 (2023), against an average of $53615.9.
- Across the five-year window, Asset Writedowns and Impairment soared 2590.3% in 2023 and soared 1127.15% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $6250.0 in 2022, then jumped by 122.1% to $13881.0 in 2023, then plunged by 172.04% to -$10000.0 in 2024, then jumped by 367.15% to $26715.0 in 2025.
- Per Business Quant, the three latest GRUSF Asset Writedowns and Impairment figures stand at $26715.0 (Q1 2025), -$10000.0 (Q3 2024), and $2177.0 (Q1 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 26,715.00 |
| Mar 31, 2025 | 26,715.00 |
| Sep 30, 2024 | -10,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Mar 31, 2024 | 2,177.00 |
| Mar 31, 2024 | 2,177.00 |
| Oct 31, 2023 | 13,881.00 |
| Oct 31, 2023 | 13,881.00 |
| Apr 30, 2023 | 168,144.00 |
| Apr 30, 2023 | 168,144.00 |
| Jan 31, 2023 | 168,144.00 |
| Jan 31, 2023 | 168,144.00 |
| Jan 31, 2022 | 6,250.00 |
| Jan 31, 2022 | 6,250.00 |
| Oct 31, 2020 | -962.00 |
| Oct 31, 2020 | -962.00 |
| Jul 31, 2020 | -12,433.00 |
| Jul 31, 2020 | -12,433.00 |
| Apr 30, 2020 | 10,370.00 |
| Apr 30, 2020 | 10,370.00 |